Brief: Astrazeneca-Ultomiris Demonstrated 43.4% Reduction In Proteinuria Versus Placebo In Adults With Immunoglobulin A Nephropathy At 34 Weeks In Phase III Trial
06/06/2026 10:29
BRIEF-Astrazeneca-Ultomiris Demonstrated 43.4% Reduction In Proteinuria Versus Placebo In Adults With Immunoglobulin A Nephropathy At 34 Weeks In Phase III Trial June 6 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA-ULTOMIRIS DEMONSTRATED 43.4% REDUCTION IN PROTEINURIA VERSUS PLACEBO IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY AT 34 WEEKS IN PHASE III TRIAL
Source text: [ID:]
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains